NealEReadyMD

Oncology • Durham, NC

Professor, Medicine, Duke University School of Medicine

Join to view full profile

Dr. Ready is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ready's full profile

Already have an account?

Office
4101 N Roxboro St
Durham, NC 27704
Phone+1 919-684-8111

Education & Training

Tufts Medical CenterFellowship, Hematology and Medical Oncology, 1992 - 1994
Roger Williams Medical CenterFellowship, Hematology and Medical Oncology, 1990 - 1992
Brown UniversityResidency, Internal Medicine, 1986 - 1989
Vanderbilt University School of MedicineClass of 1986

Certifications & Licensure

NC State Medical License 2006 - 2025
RI State Medical License 1988 - 2006
MA State Medical License 1994 - 2003
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2010-2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
America's Top Doctors for Cancer Castle Connolly, 2009-2013

Clinical Trials

Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer Start of enrollment: 2002 May 01
Completed
Phase 2
Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung Cancer Start of enrollment: 2004 Dec 01
Completed
Phase 2
Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer Start of enrollment: 2007 Mar 15
Completed
Phase 1, Phase 2
Study of Sorafenib/Cetuximab in Head and Neck Cancer Start of enrollment: 2008 Jan 01
Completed
Phase 1, Phase 2
Identification of Gene Expression Signature for Panitumumab Sensitivity in Untreated Locally Advanced SCCHN Start of enrollment: 2011 Jan 01
Terminated
Phase 2
Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2013 Mar 01
Completed
Phase 2
Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer Start of enrollment: 2013 Jul 01
Completed
Phase 1, Phase 2
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) Start of enrollment: 2014 Mar 27
Completed
Phase 3
Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer Start of enrollment: 2016 Jan 25
Completed
Phase 2
Neoadjuvant Pembrolizumab Start of enrollment: 2017 Jan 01
Active, not recruiting
Phase 2
A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer Start of enrollment: 2016 Dec 01
Terminated
Phase 2
TOP 2301: Neoadjuvant Chemo for NSCLC Start of enrollment: 2024 Jul 01
Not yet recruiting
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

385 citations
Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
Scott N. Gettinger, Naiyer A. Rizvi, Laura Qm Chow, Hossein Borghaei, Julie R. Brahmer
Journal of Clinical Oncology. 2016-09-27
6328 citations
Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
Julie R. Brahmer, Karen L. Reckamp, Paul Baas, Lucio Crinò, Wilfried Eberhardt
The New England Journal of Medicine. 2015-07-08
1536 citations
First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
David P. Carbone, Martin Reck, Luis Paz-Ares, Benjamin C. Creelan, Leora Horn
The New England Journal of Medicine. 2017-06-21